Local Paclitaxel Delivery to Prevent Restenosis in Peripheral Arterial Disease (ResTAP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03858764|
Recruitment Status : Withdrawn (no patients enrolled. primary investigator never started study)
First Posted : March 1, 2019
Last Update Posted : March 4, 2019
|Condition or disease|
|Peripheral Arterial Disease Restenosis|
Peripheral arterial disease (PAD) of the lower extremities is an extremely prevalent, and often times, disabling disorder reaching roughly 8 million people in the United States, and up to 20 percent of the population over the age of 60 to 70. Atherosclerosis commonly occurs in the superficial femoral artery (SFA) and the popliteal artery limiting blood flow to the affected vessels, as well as, the distal lower extremities. PAD of this type causes claudication in up to 35% of patients which may progress to critical limb ischemia in up to 2%.
Endovascular treatment options have significantly improved over the past decade, allowing a multitude of treatment alternatives. In the US, the number of endovascular treatments now exceed bypass surgery. Procedural success rates of greater than 90 percent can be achieved by stenting, atherectomy, and percutaneous transluminal angioplasty; however, long term patency rates have been troubled by elastic recoil or neointimal hyperplasia. Two year patency rates have been documented to range from 40-50% following balloon angioplasty. Stenting in the femoropopliteal region in attempts to improve restenosis fall short with a primary patency rate of 70-80% as seen in the FAST trial. Atherectomy is promising, but has not been studied extensively.
The inability to obtain long term patency has led us to look at our success in the coronary field where drug-eluting stents (DES) are often used. Antiproliferative drugs such as paclitaxel prevent neointimal growth and have proven patency and long term success. There have been initial animal and human studies which have shown potential in preventing restenosis by using drug coated balloons and DES. Currently, there is no FDA approved drug eluting balloon for use in femoropopliteal disease, leading us to search for alternative therapies following femoropopliteal interventions.
Paclitaxel inhibits microtubule disassembly and disrupts normal cellular processes such as protein signaling, mitosis, and migration. It is highly lipogenic and poorly water soluble. Paclitaxel has been stated to prevent restenosis through several mechanisms in vitro. These mechanisms include inhibiting proliferation and migration of human smooth muscle cells. Use of the antiproliferative agent in the peripheral arena has been conducted, but no definitive results have been achieved to date. One internal animal study showed promise in the deliverability of localized paclitaxel into targeted segments of the vessel using the TAPAS device. Concentrations of 0.67 mg/mL, 1.2 mg/mL, and 2.0 mg/mL were infused locally at a duration of 2-5 minutes within the iliofemoral segment in pigs, then aspirated from the vessel using the device. No differences in drug absorption were found among the three concentrations. Drug retention remained greater than 50% in all groups at 3 and 24 hours. The average drug concentration in the vessel wall of all groups was 1.73 ± 0.85 µg/g at 3 hours, and 1.29 ± 0.47 µg/g at 24 hours after treatment. Approximately 77% of the total drug administered was aspirated, with the assumption that the remaining drug was either absorbed in the tissue, remained in the catheter, or lost systemically. On average, plasma paclitaxel levels after treatment measured 22.5 ± 21.07 ng/mL at 2 minutes, 2.7 ± 0.85 ng/mL at 3 hours, and less than 1.2 ng/mL at 24 hours. Histology showed no inflammation, injury, or other adverse effect when compared with the contrast group.
The newly available Targeted Adjustable Pharmaceutical Application System (TAPAS)-TAPAS Catheter Therapeutic System (Spectranetics, Colorado Springs, CO, USA)-has a proximal and distal occlusion balloon with an adjustable length that allows local drug delivery to a targeted arterial segment preventing systemic effects by allowing aspiration following delivery.
The ResTAP study is a prospective, open label, observational study to assess the safety and efficacy of the delivery of paclitaxel to prevent recurrent restenosis after percutaneous intervention including atherectomy with or without stenting in patients who have restenosis after a prior endovascular revascularization.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Local Paclitaxel Delivery to Prevent Restenosis Using the TAPAS Catheter After Endovascular Revascularization in Patients With Previous Femoropopliteal Intervention|
|Study Start Date :||August 2013|
|Actual Primary Completion Date :||August 2013|
|Actual Study Completion Date :||August 2013|
- Primary Patency [ Time Frame: 6 months ]Loss of primary patency will occur for any clinically driven Target Lesion Revascularization (TLR) as determined by Rutherford scale on claudication and a Peak Systolic Velocity Ratio (PSVR) of > 2.5 on Duplex Ultrasound (DUS), or CTA quantified stenosis ≥ 70%
- Primary Safety [ Time Frame: 1 month ]Freedom from death, major amputation in the target limb, or Target Lesion Revascularization (either surgical or endovascular)
- Primary Patency [ Time Frame: 1, 3, and 12 months ]Loss of primary patency will occur for any clinically driven Target Lesion Revascularization (TLR) or a Peak Systolic Velocity Ratio (PSVR) of > 2.5 on Duplex Ultrasound (DUS), CTA quantified stenosis ≥ 70%
- Primary Assisted Patency [ Time Frame: 6, 12 months ]Patency of the target vessel regardless of secondary interventions performed to restore blood flow after restenosis.
- Secondary Patency [ Time Frame: 6, 12 months ]Patency of the target vessel regardless of secondary interventions performed to restore blood flow after re-occlusion
- Functional Status [ Time Frame: 1, 3, 6, and 12 months ]Rutherford Classification
- Secondary Safety [ Time Frame: 1, 3, 6, 12 months ]adverse events associated with the use of paclitaxel, such as, but not limited to: hypotension, anaphylactic reactions, nausea, vomiting, diarrhea pancytopenia, neuropathy, alopecia which will be determined by clinical assessment and review of systems at time of exam